Hansoh Pharmaceutical Submits HS‑10365 NDA to NMPA for RET‑Positive NSCLC
CompanyDrug

Hansoh Pharmaceutical Submits HS‑10365 NDA to NMPA for RET‑Positive NSCLC

Jiangsu Hengrui Secures NMPA Approval to Launch Phase III Trial of Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
CompanyDrug

Jiangsu Hengrui Secures NMPA Approval to Launch Phase III Trial of Trastuzumab Rezetecan in HER2‑Positive Breast Cancer

NMPA Expands Reference Listed Drugs List to 98 Items for Chemical Generic Drugs
Policy / Regulatory

NMPA Expands Reference Listed Drugs List to 98 Items for Chemical Generic Drugs

GSK Secures FDA Approval for Blenrep in Multiple Myeloma
CompanyDrug

GSK Secures FDA Approval for Blenrep in Multiple Myeloma

Pfizer R&D & ATLATL Forge Open Innovation Partnership in Beijing
CompanyDeals

Pfizer R&D & ATLATL Forge Open Innovation Partnership in Beijing

RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform
CompanyDrug

RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform

Astellas China Secures GBA Approval for First‑in‑Class Fezolinetant (VEOZA)
CompanyDrug

Astellas China Secures GBA Approval for First‑in‑Class Fezolinetant (VEOZA)

Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing
CompanyDrug

Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing

Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans
CompanyDrug

Shanghai CirCode Biomed Secures FDA Orphan Designation for HM2003 Injection in Thromboangiitis Obliterans

Huadong’s Mefatinib Approved by NMPA for EGFR‑Driven NSCLC
CompanyDrug

Huadong’s Mefatinib Approved by NMPA for EGFR‑Driven NSCLC

Hengrui Launches Henagliflozin Triple‑Combination Metformin for Type 2 Diabetes
CompanyDrug

Hengrui Launches Henagliflozin Triple‑Combination Metformin for Type 2 Diabetes

CSPC’s SYH2061 Injection Receives NMPA Clinical‑Trial Approval for IgA Nephropathy
CompanyDrug

CSPC’s SYH2061 Injection Receives NMPA Clinical‑Trial Approval for IgA Nephropathy